Answers are grounded in this paper and cite their sources.
This invited editorial refers to ‘Agreement between PAWP and LVEDP during invasive cardiopulmonary exercise testing and comparison of prognostic performances’, by R. Hortegal et al. https://doi.org/10.1016/j.cardfail.2025.10.017 Yentl, the 19th-century heroine of Isaac Bashevis Singer’s short story, had to disguise herself as a man to attend school and study the Talmud. […] Being different from men has meant being second-class and less than equal […]. It may therefore be sad, but not surprising, that women have too often been treated less than equally in social relations, political endeavors, business, education, research, and health care. Healy B, NEJM 19911 Wild-type amyloid transthyretin cardiomyopathy (ATTRwt-CM) has long been regarded as an uncommon disorder of elderly men.2 This view is increasingly difficult to sustain: population-based and prospective screening studies in elderly and at-risk populations suggest that ATTRwt-CM is more prevalent than many conditions formally classified as rare diseases3–5 and that women account for a meaningful proportion of detected cases.4,5 Yet women remain underrepresented in therapeutic trials, limiting the precision of sex-specific estimates of efficacy and safety.2 In ATTR-ACT, tafamidis reduced all-cause mortality and cardiovascular hospitalizations in ATTR-CM, but women comprised only a small minority of participants.6 Subsequent Phase 3 trials have broadened the therapeutic landscape, with patisiran preserving functional capacity and health status in APOLLO-B6 and vutrisiran reducing the risk of death and recurrent cardiovascular events in HELIOS-B.6 Despite this progress, randomized evidence still provides limited resolution on sex-specific outcomes. At the same time, real-world studies consistently show that ATTR-CM is often diagnosed only after a delay of several years, following multiple clinical encounters and misclassifications.7 This delay may be amplified in women, whose presentation is more likely to be attributed to alternative diagnoses.
No takes yet. Share an insight, caveat, or question.
Poletti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: